Heparin Cofactor B
Heparin Cofactor B Uses, Dosage, Side Effects, Food Interaction and all others data.
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
Hereditary AT deficiency causes an increased risk of venous thromboembolism (VTE). During high-risk situations such as surgery or trauma or for pregnant women, during the peri-partum period, the risk of development of VTEs as compared to the normal population in these situations is increased by a factor 10 to 50. In hereditary antithrombin deficient patients ATryn restores (normalize) plasma AT activity levels during peri-operative and peri-partum periods.
| Trade Name | Heparin Cofactor B |
| Generic | Antithrombin III human |
| Antithrombin III human Other Names | Antithrombin III, Antithrombin III (human), Antithrombin III human, Antithrombin III human plasma-derived, Antithrombin III, human, Antithrombin III,human, Antitrombina III, AT-III, Heparin cofactor B |
| Type | |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Heparin Cofactor B is an alpha-2-glycoprotein used to prevent thromboembolisms in patients with hereditary antithrombin III deficiency.
Heparin Cofactor B is a human antithrombin (AT) indicated in patients with hereditary antithrombin deficiency for the treatment and prevention of thromboembolism and prevention of peri-operative and peri-partum thromboembolism
Heparin Cofactor B is also used to associated treatment for these conditions: Hereditary antithrombin III deficiency
How Heparin Cofactor B works
Antithrombin, an alpha2-glycoprotein of molecular weight 58,000, is normally present in human plasma at a concentration of approximately 12.5 mg/dL and is the major plasma inhibitor of thrombin. Inactivation of thrombin by AT occurs by formation of a covalent bond resulting in an inactive 1:1 stoichiometric complex between the two, involving an interaction of the active serine of thrombin and an arginine reactive site on AT. AT is also capable of inactivating other components of the coagulation cascade including factors IXa, Xa, XIa, and XIIa, as well as plasmin. The neutralization rate of serine proteases by AT proceeds slowly in the absence of heparin, but is greatly accelerated in the presence of heparin. As the therapeutic antithrombotic effect of heparin is mediated by AT, heparin in vivo is ineffective in the absence or near absence of AT. After administration, Heparin Cofactor B temporarily replaces the missing AT in patients with hereditary antithrombin deficiency.
Food Interaction
- Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.
Volume of Distribution
Distributed into plasma (39%), extravascular space (49%), and vascular endothelial cells (11%).
Elimination Route
Therapeutic target plasma concentrations in patients with congenital antithrombin III deficiency range from 80–120% of values in healthy adults. At plasma concentrations ≤70% of normal, increased thrombin generation. Supraphysiologic plasma concentrations (e.g., 150–200% of normal) have increased bleeding risk in patients with sepsis and disseminated intravascular coagulation, not known whether supraphysiologic concentrations increase bleeding risk in patients with congenital antithrombin III deficiency.
Half Life
2.5 - 3.8 hs
Elimination Route
Complexes of antithrombin III with thrombin or other proteinases cleared principally by liver and excreted in urine.
Innovators Monograph
You find simplified version here Heparin Cofactor B
